{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-046722","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.598791+00:00","generated_at":"2026-06-10T23:34:22.636381+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PepGen receives Health Canada clearance to begin Phase 1 study of PGN-EDODM1 in DM1; FDA grants Orphan Drug Designation","bullets":["Health Canada issued No Objection Letter for CTA to start FREEDOM-DM1 Phase 1 trial of PGN-EDODM1 in myotonic dystrophy type 1.","FDA granted Orphan Drug Designation to PGN-EDODM1 for the treatment of DM1.","Phase 1 study is a randomized, placebo-controlled, SAD study enrolling ~24 adults; dose escalation from 5 mg/kg to 10 mg/kg then 20 mg/kg.","Initial results from the FREEDOM-DM1 study are expected in 2024.","FDA clinical hold on US IND for PGN-EDODM1 remains; company continues working to resolve it."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-046722","json":"https://secwatch.observer/filing/0000950170-23-046722.json","markdown":"https://secwatch.observer/filing/0000950170-23-046722.md","text":"https://secwatch.observer/filing/0000950170-23-046722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023046722/0000950170-23-046722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023046722/pepg-20230906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:34:22.636381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}